QIAGEN appoints Wolfgang Fries as Vice President Global Human Resources
May 03 2004

QIAGEN appoints Wolfgang Fries as Vice President Global Human Resources

Venlo, The Netherlands, May 03, 2004 - QIAGEN, N.V. (Nasdaq: QGENF; Frankfurt, Prime Standard: QIA) today announced that Wolfgang Fries has joined QIAGEN and has assumed responsibility for QIAGEN's world wide human resource management as Vice President Global Human Resources starting April 1, 2004. Mr. Fries will be a member of QIAGEN's Executive Committee and will be based in QIAGEN's European headquarters in Hilden. He will report to Peer M. Schatz, QIAGEN's Chief Executive Officer. In the newly created position as QIAGEN's Vice President Global Human Resources Mr. Fries will focus for on building, attracting and retaining exceptional talent at QIAGEN.

Mr. Fries brings almost twenty years of experience with significant responsibility in the global automotive supply business as Labor Director (Faurecia- SAI Automotive AG) and Human Resources Manager (Valeo) and the automotive industry (AUDI AG). In those industries he was responsible for HR matters in areas including research and development, sales and marketing, engineering and design. Prior to joining QIAGEN, Mr. Fries was Vice President Human Resources global of GDX Automotive, a subsidiary of GenCorp Inc. (NYSE: GY) in Farmington Hills, USA.

"QIAGEN's success is fueled by our employees and our exceptionally strong corporate culture which is defined by excellence, leadership and commitment to our customer's success. Wolfgang's expertise in human resources will contribute to our strong leadership in our markets by enabling all QIAGEN employees to more effectively contribute towards our shared mission," said Peer M. Schatz, QIAGEN's Chief Executive Officer. "


QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,600 people worldwide. Further information on QIAGEN can be found at www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).



Peer M. Schatz
Chief Executive Officer
+49 2103 29 11702
e-mail: peer.schatz@QIAGEN.com


Dr. Solveigh Mähler
Manager Investor Relations
+49 2103 29 11710
e-mail: solveigh.maehler@QIAGEN.com


Share this page